Recombinant human alpha galactosidase AAlternative Names: GC1119
Latest Information Update: 07 Jul 2016
At a glance
- Originator Green Cross
- Class Carminatives; Enzymes; Recombinant proteins
- Mechanism of Action Alpha glucosidase replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fabry's disease
Most Recent Events
- 26 Jul 2013 Phase-I development is ongoing in South Korea
- 30 Jul 2012 Phase-I clinical trials in Fabry's disease in South Korea (IV) (NCT01653444)